Invesco’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-340,654
| Closed | -$34.7M | – | 3930 |
|
|
2023
Q2 | $34.7M | Sell |
340,654
-62,902
| -16% | -$5.95M | 0.01% | 1093 |
|
|
2023
Q1 | $36.7M | Buy |
403,556
+313,452
| +348% | +$18.4M | 0.01% | 1084 |
|
|
2022
Q4 | $3.42M | Buy |
90,104
+62,997
| +232% | +$2.17M | ﹤0.01% | 2426 |
|
|
2022
Q3 | $681K | Buy |
27,107
+330
| +1% | +$9.15K | ﹤0.01% | 3080 |
|
|
2022
Q2 | $814K | Sell |
26,777
-29,335
| -52% | -$875K | ﹤0.01% | 3081 |
|
|
2022
Q1 | $1.84M | Sell |
56,112
-2,224,297
| -98% | -$66M | ﹤0.01% | 2819 |
|
|
2021
Q4 | $60.1M | Sell |
2,280,409
-1,158,395
| -34% | -$89.6M | 0.01% | 972 |
|
|
2021
Q3 | $346M | Buy |
3,438,804
+629,088
| +22% | +$73.7M | 0.09% | 280 |
|
|
2021
Q2 | $398M | Buy |
2,809,716
+753,356
| +37% | +$85.1M | 0.1% | 259 |
|
|
2021
Q1 | $205M | Buy |
2,056,360
+276,885
| +16% | +$32.3M | 0.05% | 468 |
|
|
2020
Q4 | $220M | Buy |
1,779,475
+1,216,844
| +216% | +$160M | 0.06% | 390 |
|
|
2020
Q3 | $54.8M | Buy |
562,631
+509,453
| +958% | +$63.7M | 0.02% | 901 |
|
|
2020
Q2 | $8.3M | Buy |
53,178
+51,583
| +3,234% | +$7.84M | ﹤0.01% | 1741 |
|
|
2020
Q1 | $231K | Sell |
1,595
-50,342
| -97% | -$9.72M | ﹤0.01% | 3355 |
|
|
2019
Q4 | $10.6M | Buy |
+51,937
| New | +$9.47M | ﹤0.01% | 1731 |
|
|
2019
Q3 | – | Sell |
-18,750
| Closed | -$1.77M | – | 3736 |
|
|
2019
Q2 | $1.77M | Buy |
18,750
+192
| +1% | +$16.6K | ﹤0.01% | 2766 |
|
|
2019
Q1 | $1.59M | Buy |
18,558
+14,276
| +333% | +$1.19M | ﹤0.01% | 2769 |
|
|
2018
Q4 | $240K | Buy |
+4,282
| New | +$261K | ﹤0.01% | 3516 |
|
Other funds holding RETA
Invesco's RETA Position: Q3 2023 in Review
Invesco sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 340,654 shares — an estimated $34.7M sold.
Invesco first reported a position in RETA in Q4 2018 and held it in 18 quarters. The position peaked at $398M in Q2 2021. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.
- Invesco reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
- Invesco sold 340,654 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $34.7M.
- Invesco first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q4 2018 and held it in 18 quarters.
- Invesco's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $398M in Q2 2021.
- 2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.
Based on Invesco's 13F filing for Q3 2023, filed 13 Nov 2023.